Open AccessRationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy
Author(s) -
Nicole L. Michmerhuizen,
Jennifer C. Owen,
Molly E. Heft Neal,
Jacqueline E. Mann,
Elizabeth Leonard,
J Wang,
Jingyi Zhai,
Hui Jiang,
Jonathan B. McHugh,
J. Chad Brenner,
Mark E. Prince
Publication year - 2020
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-020-03418-7
Subject(s) - pi3k/akt/mtor pathway , cancer research , targeted therapy , chordoma , pten , cyclin dependent kinase , sunitinib , imatinib , protein kinase b , biology , medicine , cell cycle , apoptosis , pathology , cancer , genetics , myeloid leukemia
Chordomas are rare and serious tumors with few effective treatments outside of aggressive surgery and radiation. Targeted therapies may present a more effective option for a subset of patients with lesions possessing certain genetic biomarkers.